Emergent BioSolutions’ (EBS) Buy Rating Reiterated at Benchmark

Benchmark restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a report released on Tuesday morning, Benzinga reports. They currently have a $8.00 price objective on the biopharmaceutical company’s stock.

Emergent BioSolutions Stock Performance

EBS opened at $7.50 on Tuesday. The company has a market capitalization of $392.74 million, a price-to-earnings ratio of -0.68 and a beta of 1.62. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $8.29. The business has a 50 day moving average price of $5.20 and a two-hundred day moving average price of $3.29.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of ($3.65) by $4.24. The firm had revenue of $300.40 million during the quarter. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. During the same quarter last year, the company earned ($3.17) earnings per share. Research analysts predict that Emergent BioSolutions will post -1.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kathryn C. Zoon sold 10,000 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the sale, the director now owns 54,482 shares in the company, valued at approximately $332,885.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 12,919 shares of company stock worth $75,831 over the last ninety days. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Emergent BioSolutions

A number of institutional investors and hedge funds have recently modified their holdings of the stock. CoreCap Advisors LLC acquired a new stake in Emergent BioSolutions during the 4th quarter valued at $33,000. Avidian Wealth Solutions LLC acquired a new stake in Emergent BioSolutions during the 1st quarter valued at $33,000. Tidal Investments LLC acquired a new stake in Emergent BioSolutions during the 1st quarter valued at $34,000. Laurion Capital Management LP acquired a new stake in Emergent BioSolutions during the 3rd quarter valued at $37,000. Finally, Tower Research Capital LLC TRC raised its stake in Emergent BioSolutions by 52.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,823 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.